Recurrence rates of excised keloids treated with postoperative triamcinolone acetonide injections or interferon alfa-2b injections.
BACKGROUND
Keloids that are surgically removed commonly recur within the excision sites.


OBJECTIVE
Our purpose was to determine whether postsurgical adjunctive therapy reduces such recurrences.


METHODS
We determined the rate of recurrence after excision alone (n = 43) and postoperative injection with triamcinolone acetonide (TAC; n = 65) or interferon alfa-2b (IFN-alpha 2b; n = 16).


RESULTS
Of lesions excised without postoperative injections, 51.1% (22 of 43) recurred; 58.4% of TAC-treated lesions (38 of 65) recurred and 18.7% of IFN-alpha 2b-treated lesions (3 of 16) recurred (p = 0.025).


CONCLUSIONS
Postoperative TAC injections do not reduce the number of keloid recurrences. However, injection of keloid excision sites with IFN-alpha 2b offers a therapeutic advantage over keloid excision.
Berman
B
B
Department of Dermatology and Cutaneous Surgery, University of Miami School of Medicine, FL 33136, USA.
Flores
F
F
D000293:Adolescent; D000328:Adult; D017024:Chemotherapy, Adjuvant; D002648:Child; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015552:Injections, Intralesional; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D007627:Keloid / Q000188:drug therapy* / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D011182:Postoperative Care; D011994:Recombinant Proteins; D012008:Recurrence; D012189:Retrospective Studies; D014222:Triamcinolone Acetonide / Q000008:administration & dosage*
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D014222:Triamcinolone Acetonide